Key Insights

Highlights

Success Rate

94% trial completion (above average)

Published Results

316 trials with published results (34%)

Research Maturity

757 completed trials (81% of total)

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 17/100

Termination Rate

5.2%

49 terminated out of 940 trials

Success Rate

93.9%

+7.4% vs benchmark

Late-Stage Pipeline

29%

271 trials in Phase 3/4

Results Transparency

42%

316 of 757 completed with results

Key Signals

316 with results94% success49 terminated

Data Visualizations

Phase Distribution

696Total
Not Applicable (203)
Early P 1 (4)
P 1 (100)
P 2 (118)
P 3 (165)
P 4 (106)

Trial Status

Completed757
Unknown74
Terminated49
Withdrawn20
Recruiting18
Active Not Recruiting11

Trial Success Rate

93.9%

Benchmark: 86.5%

Based on 757 completed trials

Clinical Trials (940)

Showing 20 of 20 trials
NCT07177339Phase 3RecruitingPrimary

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

NCT06712563Active Not RecruitingPrimary

Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting

NCT07714252Not ApplicableNot Yet Recruiting

Virtual Nurse and Social Worker Palliative Care Team to Improve Quality of Life in Veterans With Heart Failure or COPD

NCT00668772Phase 3TerminatedPrimary

Tiotropium/Salmeterol Inhalation Powder in COPD

NCT05718102Not ApplicableActive Not RecruitingPrimary

Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD

NCT07252908Phase 2CompletedPrimary

A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder

NCT07649577Not ApplicableCompleted

Generative AI for Medication Counselling and Adherence in Community Pharmacies

NCT03718780Not ApplicableCompletedPrimary

Assessment of Continuous Measurement of Transcutaneous CO2 for Evaluation of Alveolar Dead Space During Exercise

NCT06367686Completed

Detecting Systemic Carbon Dioxide Levels With a Novel Biosensor

NCT06979518Phase 1CompletedPrimary

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry

NCT04669743Not ApplicableActive Not RecruitingPrimary

Innate Immunity in Ozone-induced Airway Inflammation in COPD

NCT04939454Not ApplicableCompletedPrimary

Involvement of Skeletal Muscle Fibrocytes in sarcOpenia in Patients With Chronic ObstRuctive Pulmonary Disease

NCT06154837Phase 1Active Not RecruitingPrimary

A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease

NCT06890208Completed

Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures, Third Wave

NCT06831994Not ApplicableActive Not Recruiting

Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity

NCT02655302Not ApplicableTerminatedPrimary

Study of the Involvement of IL-17 / IL-22 Pathway in Bacterial Exacerbations of COPD

NCT06755008Not ApplicableRecruitingPrimary

Benefits of Epithelial Repair in COPD by Induced Pluripotent Stem Cells (iPS)

NCT04027296CompletedPrimary

Development and Validation of the GLORI-COPD Score

NCT05006560Not ApplicableCompletedPrimary

Internet-based Rehabilitation Aftercare Focusing on Physical Activity Promotion in Persons With COPD

NCT05704881RecruitingPrimary

Monitoring of the End-tidal Carbon Dioxide (EtCO2) as a Severity Criterion in COPD Exacerbations

Scroll to load more

Research Network

Activity Timeline